Agenus (NASDAQ:AGEN) Issues Quarterly Earnings Results

Agenus (NASDAQ:AGEN) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.36) by $0.32, Zacks reports. The company had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million.

Agenus Stock Performance

Agenus stock opened at $1.87 on Thursday. The stock has a market capitalization of $43.87 million, a P/E ratio of -0.17 and a beta of 1.23. The company’s fifty day moving average price is $3.23 and its 200 day moving average price is $3.84. Agenus has a 1 year low of $1.86 and a 1 year high of $19.69.

Wall Street Analysts Forecast Growth

AGEN has been the subject of several recent research reports. Robert W. Baird reduced their price target on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday. HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.75.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.